Literature DB >> 29682141

Communicating hydrocephalus and coexisting nonenhancing tumor: An ominous sign for patients with neurofibromatosis type 1?

Ryo Miyahara1, Satoshi Tsutsumi1, Satoshi Adachi2, Hisato Ishii1, Akihide Kondo2, Yukimasa Yasumoto1.   

Abstract

A 26-year-old woman with familial neurofibromatosis type 1 sustained headache that worsened for 1 month. Neuroimaging revealed a mild ventriculomegaly and nonenhancing lesion in the pons. In spite of repeated cerebrospinal fluid examinations and magnetic resonance imaging, the etiology was not determined. The affected pons markedly enlarged in the following 2 months, with extensive leptomeningeal dissemination. Biopsy through hemilaminectomy of the T9 was diagnosed as glioblastoma multiforme. Prompt histologic examination should be performed when patients with familial neurofibromatosis type 1 manifest communicating hydrocephalus coexistent with a nonenhancing tumor.

Entities:  

Keywords:  Communicating hydrocephalus; Leptomeningeal GBM; Neurofibromatosis type 1; Nonenhancing pontine tumor

Year:  2018        PMID: 29682141      PMCID: PMC5909025          DOI: 10.1016/j.radcr.2018.03.021

Source DB:  PubMed          Journal:  Radiol Case Rep        ISSN: 1930-0433


  14 in total

1.  Leptomeningeal infiltration as the presenting manifestation of a malignant glioma.

Authors:  L C Wheen; N E Anderson; P C H Baker; V K Singh; B J L Synek
Journal:  J Clin Neurosci       Date:  2006-01-23       Impact factor: 1.961

2.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013.

Authors:  Quinn T Ostrom; Haley Gittleman; Jordan Xu; Courtney Kromer; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2016-10-01       Impact factor: 12.300

3.  Aggressive leptomeningeal gliomatosis in neurofibromatosis type 1.

Authors:  David Arkadir; Yakov Fellig; Moshe John Gomori; Eduard Linetsky; Edna Shalom; Alexander Lossos
Journal:  J Clin Oncol       Date:  2012-08-06       Impact factor: 44.544

4.  The incidence and significance of multicentric noncontrast-enhancing lesions distant from a histologically-proven glioblastoma.

Authors:  Arian Lasocki; Frank Gaillard; Mark A Tacey; Katharine J Drummond; Stephen L Stuckey
Journal:  J Neurooncol       Date:  2016-07-13       Impact factor: 4.130

5.  Endoscopic Third Ventriculostomy in Patients with Neurofibromatosis Type 1: A Multicenter International Experience.

Authors:  Jonathan Roth; Roee Ber; Jeffrey H Wisoff; Eveline T Hidalgo; David D Limbrick; Daniel S Berger; Ulrich W Thomale; Matthias Schulz; Giuseppe Cinalli; Claudia Santoro; Shlomi Constantini
Journal:  World Neurosurg       Date:  2017-08-24       Impact factor: 2.104

Review 6.  Primary leptomeningeal glioblastoma with systemic metastases-case report and review of literature.

Authors:  Girish Bathla; Sarika Gupta; Toshio Moritani
Journal:  Clin Imaging       Date:  2015-04-07       Impact factor: 1.605

7.  Altered cerebrospinal fluid dynamics in neurofibromatosis type l: severe arachnoid thickening in patients with neurofibromatosis type 1 may cause abnormal CSF dynamic.

Authors:  Young Sill Kang; Eun-Kyung Park; Yong-Oock Kim; Ju-Seong Kim; Dong-Seok Kim; U W Thomale; Kyu-Won Shim
Journal:  Childs Nerv Syst       Date:  2017-03-22       Impact factor: 1.475

8.  Diffuse leptomeningeal seeding from a malignant spinal cord astrocytoma in a child with neurofibromatosis.

Authors:  B L Maria; L L Cafferty; H S Singer; J I Epstein; B S Carson
Journal:  J Neurooncol       Date:  1986       Impact factor: 4.130

Review 9.  Adult Glioblastoma.

Authors:  Brian M Alexander; Timothy F Cloughesy
Journal:  J Clin Oncol       Date:  2017-06-22       Impact factor: 44.544

Review 10.  Leptomeningeal spinal metastases from glioblastoma multiforme: treatment and management of an uncommon manifestation of disease.

Authors:  Cort D Lawton; Daniel T Nagasawa; Isaac Yang; Richard G Fessler; Zachary A Smith
Journal:  J Neurosurg Spine       Date:  2012-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.